Articles

This article covers its structure, mechanism, and research findings — including human clinical trial data, GHRH-knockout mouse research, and corrections to two citation issues found in the source material, one involving a duplicated/misattached reference and one involving a pharmacokinetic claim sourced to a study that isn't actually a pharmacology paper.

MT1 is hypothesized to act primarily through MC1R, a Gs-coupled receptor expressed predominantly on melanocytes, triggering a cAMP-driven signaling cascade that promotes eumelanin synthesis.

This article covers its receptor mechanism, evidence across bone, nitrogen, and energy-balance research, and corrects a significant framing issue in secondary literature: a human pharmacokinetic trial in this compound's own history is commonly described as testing "mammalian models" rather than the human volunteers it actually involved.

This article covers each component's proposed mechanism and research findings, and flags several citation and terminology issues found in secondary source material on this blend. It is part of the broader peptide research library maintained by Dragon Pharma Peptides.

Unlike many research peptides, GHRP-2 carries a substantial human clinical trial history — spanning GH-deficient children, adults with genetic GHRH-R mutations, and healthy-volunteer studies — though much of that history is obscured in secondary sources under vague "mammalian model" language. This article corrects that framing and organizes the mechanism and evidence by actual study population.

This article covers their coordination chemistry, proposed mechanisms, and research findings across evidence tiers — including one genuine human clinical trial that source material often obscures under vague "subjects" language.

Although both compounds are designed to promote anabolic activity, they differ significantly in their chemical structure, effects on muscle development, and typical applications during training cycles.

It is distinguished from most research peptides by an unusually strong human clinical trial record, including multiple Phase III studies. This article organizes its molecular identity, proposed mechanism, and clinical research findings, with direct links to the primary literature.

AOD-9604 was developed by researchers at Monash University, Australia, who identified the C-terminal fragment of hGH as the domain responsible for its lipolytic activity, distinct from the N-terminal/central domains responsible for receptor binding and IGF-1 stimulation.

This article organizes the receptor pharmacology, signaling mechanisms, and evidence base for each component, clarifies a common naming confusion in this compound class, and distinguishes human, animal, and in vitro findings throughout.

It combines a growth hormone-releasing hormone (GHRH) analogue with two growth hormone secretagogue receptor (GHS-R) agonists, enabling examination of parallel receptor engagement and downstream signaling coordination.

It combines an HDM-2-binding sequence from the p53 tumor suppressor protein (residues 12–26) with a cell-penetrating leader sequence derived from the Drosophila Antennapedia homeodomain protein.